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Studies in cardiology often record the time to multiple disease events such as death, myocardial infarction, or hospitalization. Competing risks
methods allow for the analysis of the time to the first observed event and the type of the first event. They are also relevant if the time to a specific
event is of primary interest but competing eventsmay preclude its occurrence or greatly alter the chances to observe it.We give a non-technical
overview of competing risks concepts for descriptive and regression analyses. For descriptive statistics, the cumulative incidence function is the
most important tool. For regression modelling, we introduce regression models for the cumulative incidence function and the cause-specific
hazard function, respectively. We stress the importance of choosing statistical methods that are appropriate if competing risks are present.
We also clarify the role of competing risks for the analysis of composite endpoints.
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Introduction
Many cardiovascular studies use the time to some disease events as
their primary outcome and hence, statistical methods developed
for survival data are usually applied. However, in some instances,
the time to a specific event is of primary interest but competing
events may preclude its occurrence or greatly alter the chances
to observe it. In other situations, different types of events may all
be relevant and the analysis may focus on both the time and
the type of the first event. In both situations, competing risks
methods, an extension of survival analysis methods, are required
for a correct analysis. In data sets, competing risks outcomes are
usually recorded as a multi-component endpoint of two variables:
one variable describes the time to the first observed event and
the second the type of the first event (either the ‘event of interest’
or a ‘competing event’).
As an example, the prediction of coronary heart disease (CHD) in
elderly subjects is complicated by the fact that a substantial propor-
tion of them may die from causes other than CHD prior to CHD
onset and the outcome would be recorded as the time to CHD or
death from other causes, whichever occurs first, and the event
type (CHD or prior death).1 As another example, randomized con-
trolled trials (RCTs) in cardiology frequently use composite end-
points, such as the time to myocardial infarction or death, to
provide an overall estimate of the effect of an intervention.2 Survival
analysis can be used to analyse the composite endpoint, but compet-
ing risks methodology may provide further insights into the effect of
interventions on the separate endpoint components.
Inmost studies, therewill be subjects forwhomthe follow-up ends
before any event can be observed. Such observations will be right-
censored at their last follow-up visit to indicate that the exact
(future) time and event type are unknown. All statistical methods
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whichwill be presented can account for right-censoring but, as in sur-
vival analysis, they are only valid if censoring is independent of the
outcome which means that subjects who are censored at a given
time point would have had the same future prognosis (i.e. they are
neither ‘sicker’ nor ‘healthier’) as those who remained in the study
beyond that time point.3,4
This article gives a non-technical overview of competing risks
concepts assuming that the reader is familiar with the basic concepts
of survival analysis.3,4 For simplicity, we discuss the situation of
two different event types only, but the methodology generalizes
seamlessly to more than two types.
Example data set
We use data from a published study of subjects with implantable
cardioverter-defibrillators (ICDs) from the ICD registry of the
Department of Cardiology, University Hospital Basel, Switzerland
for illustration.5 In brief, the study included 442 subjects with ischae-
mic or dilated cardiomyopathy with an ICD implanted for primary
(n ¼ 182) or secondary prevention (n ¼ 260), a median age of 63.4
years, and a median follow-up duration of 3.3 years. The study
aimed to quantify the benefit of ICD implantation in an unselected
routine-care population by analysing the time from ICD implantation
to the first appropriate ICD therapyor deathwithout prior appropri-
ate ICD therapy. Implantable cardioverter-defibrillator therapy that
failed to save the patient’s life at the time of the arrhythmia was clas-
sified asdeath, not as appropriate ICDtherapy.A total of 180patients
experienced an appropriate ICD therapy (and hence benefited
from implantation), 29 died without prior appropriate ICD therapy
(and hence did not benefit from implantation by termination of a
life-threatening arrhythmia event), and the remaining 233 subjects
were censored at their last follow-up visit.
Description of competing risks data
Descriptive statistics are the first step of every data analysis. We
discuss methods for competing risks that describe the occurrence
of different event types over time and can be applied to the entire
population or to subgroups defined by, e.g. treatment assignment
or age group.
The cumulative incidence function
The primary interest in describing competing risks data is often to
estimate the absolute risk of the occurrence of an event of interest
up to a follow-up timepoint t. This risk is formalizedby the cumulative
incidence function (CIF) which is defined for each event type separ-
ately and increases with time: the CIF at time t is defined as the prob-
ability that an event of that type occurs at any time point between
baseline and time t. If thedatadonot contain any censored individuals,
the CIF at time t can be estimated as the ratio of the number of
subjects who experienced that event type until time t divided by
the total number of subjects in the data set. As time increases, the
CIF increases from zero to the total proportion of events of that
type in the data.
If the data set contains censored observations, i.e. not all sub-
jects are observed to experience an event, this simple estimate
must be modified to correctly account for censoring. We
omit the details here as they are not essential for a qualitative
understanding of the CIF and have been described in many publi-
cations.6
The CIFs for the ICD data set are displayed in the left panel of
Figure 1. The estimated probability of having an appropriate ICD
therapy is 30% during the first year and 49% during the first 5 years
after ICD implantation. The estimated 5-year probability of death
without any prior ICD therapy is 10%.
Figure1 Descriptive statistics for the implantable cardioverter-defibrillator data: estimated cumulative incidence functions (left panel) and yearly
cause-specific incidence rates (right panel). Black lines correspond to events of type ‘first appropriate ICD-therapy’, solid grey line to ‘deathwithout
prior ICD-therapy’. The dashed grey line is the sum of the two cumulative incidence functions or cause-specific failure rates and denotes the total
cumulative incidence function or event rate, respectively. Numbers at the bottom of the graph are the number of subjects who are still at risk, i.e.
under follow-up and free of any event, at each time point.
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Kaplan–Meier estimation and the
cumulative incidence function
The total CIF of any first event occurring over time can be estimated
with the Kaplan–Meier estimator of the time to the first event (i.e.
using survival analysis and ignoring the event type).3,4 Alternatively,
one could estimate this quantity as the sum of the CIFs of all different
event types and, indeed, it canbe shown that this gives the same result
as the Kaplan–Meier estimator.6
It is tempting to also estimate the CIF of a specific event of interest
with the Kaplan–Meier method instead of using the estimator
described in the previous section. For this naive Kaplan–Meier estima-
tor, subjects experiencing competing events would be treated as cen-
sored observations at the time of the competing event occurrence.
While frequentlyused, it is important tonote that the logicof thismodi-
fied estimator is flawed. Treating subjects as censored indicates that
they have not yet had the event of interest up to the censoring time
but could experience that event at a future unobserved time point.
However, we do know that these subjects experienced the competing
eventandthuswillneverexperience theeventof interest as afirstevent.
It can be shown that this inappropriate treatment of competing events
causes the Kaplan–Meier estimator to over-estimate the CIF in the
presenceofcompeting risksandthat theriskover-estimation isparticu-
larly severe if the competing event is frequent.6
For the ICD example, the Kaplan–Meier ‘estimate’ of the 5-year
risk of having a first appropriate ICD therapy is 51% and the corre-
sponding risk of death without prior ICD therapy is 16%. The latter
substantially overestimates the correct CIF estimate of 10%. For
this reason the Kaplan–Meier method should not be used in the
presence of competing risks.
Some have interpreted the naive Kaplan–Meier estimate as corre-
sponding to a world, where the competing event does not exist. For
example, the 51% provided earlier would be interpreted as the risk
of an appropriate ICD therapy within 5 years in a hypothetical world
where no subject would experience the competing event, i.e. nobody
would die prior to having their first appropriate ICD therapy. The
value of statements referring to such a hypothetical world has been
hotly debated in the clinical discussion on heart valve replacement.7
Clearly, quantities such as the CIF which refer to absolute risks in the
real-world where competing events do occur seem more important
for medical decision-making. Moreover, we mentioned earlier that
the validity of all presentedmethods depends on the assumption of in-
dependent censoring. Since this approach treats subjects experiencing
competing events as censored, it implicitly assumes that the different
competing risks are independent of eachother, i.e. that subjects experi-
encing a competing event would neither have a lower nor a higher
future event rate of the event of interest than subjects without any
prior event whowere followed-up beyond that time point. The validity
of this independence assumption cannot be statistically verified and is
often clinically implausible. Specifically, in the ICD example, older sub-
jects aremore likely todie prior to an appropriate ICDtherapy, i.e. they
are ‘sicker’ than thosewho remain under follow-up, as wewill show in
the regression section below.
The cause-specific hazard function
While theCIF evaluates the cumulative probability of the occurrence
of an event at any time between baseline and a specific time point t,
the cause-specific hazard function measures the instantaneous
potential per unit time for a specific event type to occur at time t
among subject without any prior event.3 The cause-specific hazard
function is defined for each event type separately and is a function
of time: at time t, it is determined as the rate (i.e. probability per
unit time) of experiencing a specific event type during a short time-
period after time t among all subjects who have not experienced
any prior event. The rate of a specific event type can be interpreted
as the momentary ‘force’ at time t for subjects without a prior event
to experience that event type. All cause-specific event rates jointly
provide a dynamic description of the forces that draw subjects
towards the different event types as the competing risks process
evolves over time.
Different methods to estimate the cause-specific hazard function
exist andwewill explain the simplest onewhich requires first dividing
the time scale into distinct time intervals and assuming that the cause-
specific hazard is constant in each interval. The cause-specific hazard
function can thenbeestimatedby theobserved incidence rate in each
time interval. The incidence rateof aneventof interest for aparticular
time interval is defined as the number of events of interest occurring
during that time interval divided by the total observation time in that
same interval. A subject contributes observation time to a time
interval if they are still free of any event and under follow-up at the
beginning of the time interval.
The yearly incidence rates for the ICD example are given in the
right panel of Figure 1. The rate of first appropriate ICD therapies is
the highest in the first year following implantation and then decreases
sharply. The rate of death without prior appropriate ICD therapy
remains roughly constant over time at0.03 deaths per person-year
of follow-up.
To illustrate the calculation of the incidence rate for the ICD
example during Year 2 of follow-up, note that 258 subjects
were at risk (i.e. event-free and under follow-up) at the beginning
of Year 2; 25 of them had an appropriate ICD therapy and 6 of
them died without prior ICD therapy during Year 2. The total ob-
servation time in Year 2 was 212 person-years based on 179 sub-
jects contributing a full year and 79 subjects contributing an
average of 0.42 years until their event or loss to follow-up. The
resulting incidence rate in Year 2 was 25/212 ¼ 0.12 for an appro-
priate ICD therapy and 6/212 ¼ 0.03 for death without prior
ICD-therapy.
Cause-specifichazard functions aremoredifficult to interpret than
the CIF and less frequently used for descriptive purposes. However,
they do play an important role in regression modelling.
Regression models for competing
risks
Regression models assess the association between baseline covari-
ates such as treatment assignment or age with outcome. In the
competing risks context, two different approaches to regression
modelling exist: the first approach models the dependence of the
cause-specific hazard function on covariates, and the second
models the dependence of the CIF on covariates. Both approaches
are valid and the choice of the appropriate approach depends on
the research question as we show below.
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Relation between cause-specific hazard
functions and the cumulative incidence
function
We first discuss the impact of a single binary covariate such as a
treatment assignment (intervention vs. control) on the event of
interest and the competing event. As an example, let the event of
interest be fatal CHD and the competing event death from non-
coronary causes. Assume that a specific intervention reduced the
rate (i.e. the cause-specific hazard function) of fatal CHD but did
not affect the rate of death from non-coronary causes. Clearly,
we would expect such an intervention to reduce the absolute
risk of fatal CHD, but this reduced risk would leave more subjects
vulnerable to the force that draws them towards non-coronary
death. Thus, although the intervention does not affect the rate of
non-coronary deaths, we would expect to observe an increase in
the absolute risk of non-coronary deaths associated with the inter-
vention. Similarly, if an intervention reduced the rate of fatal CHD
only moderately but simultaneously reduced the rate of non-
coronary deaths dramatically it could be that the absolute risk of
fatal CHD events increased solely because the lowered event
rate of non-coronary death left more subjects at risk and evaluable
for experiencing fatal CHD. This could over-compensate and
therefore conceal the moderate rate reduction of fatal CHD
events associated with the intervention.
Thus, in the situation of competing risks, a research question rele-
vant for clinical decision-making (‘Does the intervention lower the
absolute risk of the event of interest?’) and an aetiological research
question (‘Does the intervention cause a decrease in the rate of
the event of interest amongst subjects without a prior event?’) may
have different answers. This is in contrast to survival analysis
without competing risks where there is a one-to-one association
between a decrease in the event rate and a decrease in the absolute
risk of the event. This discrepancy has been identified as a major
difficulty in the interpretation of competing risks and interferes
with a traditional understanding of disease.8,9
Regression on the cause-specific hazard
rates and regression on the cumulative
incidence function
We have seen that the effects of covariates on the CIF and the
cause-specific hazard function of the event of interest, respectively,
may differ. This implies that we have to decide which of these two
quantities to target with our regression analysis. For the purposes of
prognosis and medical decision-making, the primary interest is in
the absolute risks of the event of interest and the CIF should
thus be the target of statistical inference.10 However, our
example illustrated that to understand why an intervention affects
the CIF of the event of interest in a certain way we need to look
at its effect on both cause-specific hazard functions. Thus, to
answer aetiological research questions regression models for
cause-specific hazard functions are of primary importance
because they directly model the covariate effect on event rates
among subjects at risk.8–10 As one type of analysis does not pre-
clude the other, a deeper understanding of competing risks data
can be gained by performing both regression on the CIFs and
regression on the cause-specific hazard functions and this approach
has been recommended by some authors.9,11
Regression on the cause-specific hazard function can be per-
formed with a Cox proportional cause-specific hazards regression
model. This model assumes the same functional relationship
between the cause-specific hazard function and covariates as the
popular Cox model for survival data without competing risks does
for the relationship between the overall hazard and covariates.3,6
Technically, a cause-specific hazards model for an event of interest
can be fitted using standard statistical software for Cox regression if
competing events are treated as censored observations and, im-
portantly, this approach is valid regardless whether different
event types are independent of each other or not.6,9 The effect
measure for each covariate is a cause-specific hazard ratio (HR)
which measures how strongly the rate is affected by that covariate.
An HR ¼ 1 implies no association between the covariate and the
cause-specific hazard function, an HR . 1 implies that an increase
of the covariate value is associated with an increased rate,
whereas an HR , 1 implies that an increase in the covariate value
is associated with a reduced rate. Moreover, the further away the
HR is from 1, the larger the estimated effect per unit increase in
that covariate.
Several models for regression on the CIF have been proposed and
the most popular model is the Fine-Gray model6,12 which has also
been implemented in major statistical software packages including
R, STATA, and SAS.13,14 The resulting effectmeasure for each covari-
ate is a so-called subdistribution hazard ratio (sHR). While the nu-
merical interpretation of sHR is not straightforward, a sHR ¼ 1
implies no association between the covariate and the corresponding
CIF, a sHR. 1 implies that an increase of the covariate value is
associated with an increased risk, whereas a sHR, 1 implies the
opposite. Moreover, the further away the sHR is from 1, the larger
the estimated effect size on the CIF.
Results of multivariable regression models for the cause-specific
hazards and the CIFs of the ICD example are displayed in Table 1. If
one isprimarily interested in the aetiological questionofhowthecov-
ariates affect the rates of appropriate ICD therapy and prior death,
respectively, at each time point after implantation, the cause-specific
hazards models would be most appropriate. They show that an
advanced age (HR ¼ 1.23) and an ICD implantation for secondary
prevention (HR ¼ 2.29) both significantly increase the rate of appro-
priate shocks, butonly advancedage (HR ¼ 1.63) is significantly asso-
ciated with a higher event rate of death without prior ICD therapy.
If one is interested in predicting which patients benefit most
from ICD implantation, i.e. which patients have a high predicted
risk of receiving an appropriate (and potentially life-saving) ICD
therapy and a low risk of death without prior ICD therapy, the
regression on the CIFs would be most relevant. Both higher age
(sHR ¼ 1.19) and an ICD implantation for secondary prevention
(sHR ¼ 2.23) are associated with an increased risk of an appropri-
ate ICD therapy. There is no evidence of an association between a
secondary prevention and an increased risk of prior death. The
effect of age does also not reach conventional significance and
the estimated effect (sHR ¼ 1.40) is smaller than the correspond-
ing age effect on the rate (HR ¼ 1.63). This may be explained by
the effect of older age on the cause-specific event rate of the more
frequent endpoint of first appropriate ICD therapy which reduces
Competing risks analyses 2939
the pool (risk set) of older subjects evaluable for experiencing
prior deaths over time.
Weconcludeourdiscussionof regressionmodelling by noting that
as in survival analysis3 modelling of competing risks data requires a




According to a systematic review, 37% of published RCTs in cardi-
ology used a composite primary endpoint.2 Often, this composite
endpoint is the time to the first of several events such as death, myo-
cardial infarction, or hospitalization and the primary analysis is a
standard survival analysis which ignores the event type. The merits
and disadvantages of composite endpoints have been discussed in
manypublications15,16 andwe restrict our discussion to the contribu-
tion of competing risks analyses in this setting.
Competing risks analyses allow disentangling the contribution of
an intervention (or other covariates) on each event type separately.
Results for the ICDexampleboth for the composite endpoint and for
individual components are displayed in Table 1. For the composite
endpoint, the standard survival analysis without competing risks is
appropriate, and the effect estimates of covariates on the hazard
function and the CIF are identical. The analysis shows that both
advanced age and an ICD implantation for secondary prevention
show a highly significant association with an increased rate (and
risk) of the combined outcome of prior ICD therapy or death.
However, it is important to note that competing risks analyses
applied to composite endpoints may not always be useful and can
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Table 1 Multivariable regression models for competing risks endpoints and for the composite endpoint of the
implantable cardioverter-defibrillator data
Regression on the cause-specific hazard
functiona [HR (95% CI); P-value]
Regression on the CIFb
[sHR (95% CI); P-value]
Event: first appropriate ICD therapy
Covariates
Age (for each 10-year increase) 1.23 (1.07–1.41); P ¼ 0.003 1.19 (1.05–1.36); P ¼ 0.006
Secondary prevention (compared with primary) 2.29 (1.60–3.27); P, 0.001 2.23 (1.58–3.14); P, 0.0001
Event: death without prior ICD therapy
Covariates
Age (for each 10-year increase) 1.63 (1.11–2.39); P ¼ 0.01 1.40 (0.92–2.13); P ¼ 0.12
Secondary prevention (compared with primary) 1.25 (0.54–2.89); P ¼ 0.60 0.92 (0.39–2.15); P ¼ 0.85
Composite endpoint: first appropriate ICD therapy or prior death
Covariates
Age (for each 10-year increase) 1.28 (1.12–1.45); P, 0.001 1.28 (1.12–1.45); P, 0.001
Secondary prevention (compared with primary) 2.11 (1.52–2.93); P, 0.001 2.11 (1.52–2.93); P, 0.001
Note that the effect on the hazard function and the CIF is identical for the composite endpoint for which no competing risks are present.
HR, (cause-specific) hazard ratio; sHR, ratio of the subdistribution hazards; CI, confidence interval.
aCox proportional hazards models for cause-specific hazards for competing risks endpoints. Cox proportional hazards model for the composite endpoint.
bFine-Gray regression for competing risks endpoints. Cox proportional hazards model for the composite endpoint.
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Box 1 Competing risks: five key points
Item Description
1 Competing risks occur if the time to a specific event is of interest butother typesof eventsmaypreclude theoccurrenceof that event.More generally,
competing risks methods can be used if different types of events are studied and the focus is on the time and type of the first event.
2 The basic descriptive statistic for competing risks data is the cumulative incidence function (CIF) which describes the absolute risk of an event of
interest over time. The Kaplan–Meiermethod should not be used in the presence of competing events as it over-estimates the true absolute risk.
3 Acomplicationof competing risks is that covariates canaffect the absolute risk and the rateof aneventof interestdifferently. Regressionmodels based
on the CIF (e.g. Fine-Gray models) explore the association between covariates and the absolute risk and are therefore essential for medical
decision-making and prognostic research questions. Cause specific models for event rates (e.g. Cox proportional cause-specific hazards models)
on the other hand are to be preferred for answering aetiological research questions.
4 A complete description of competing risks data should include the modelling of all event types and not only of the event of main interest.
5 Competing risks models can assess the effect of an intervention on individual components of a composite endpoint.
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even bemisleading. First, RCTs are frequently not powered to detect
an effect of the intervention on individual components and compet-
ing risks analysis might have a low chance of detecting a true effect.
Indeed, the fact that sample size requirements for an RCT powered
to the most severe events would be prohibitively large is often the
main reason for using composite endpoints.16 Second, recent discus-
sions on composite endpoints stress the clinical importance of ana-
lyses that are not restricted to the first event but include repeated
events of the same type (e.g. hospitalizations) as well as more
severe events after the first event (e.g. deaths after a prior
stroke).17 Competing risks analyses focus on the first event and to
analyse repeated events or transitions between multiple event
types, more complex multi-state modelling would be required.6
Final remarks
This article presents an overview of competing risks concepts and
stresses the importance of using appropriate statistical methods if
competing risks are present. Key messages are summarized in Box 1.
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